516
Views
16
CrossRef citations to date
0
Altmetric
Review Article

Emerging therapies for the treatment of ungual onychomycosis

, , , , &
Pages 1575-1581 | Received 02 Jun 2014, Accepted 19 Mar 2015, Published online: 22 May 2015

References

  • Roberts DT, Taylor WD, Boyle J. Guidelines for treatment of onychomycosis. Br J Dermatol 2003;148:402–10
  • Gupta AK, Simpson F. Device-based therapies for onychomycosis treatment. Skin Therapy Lett 2012;17:4–9
  • Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998;11:415–29
  • Gupta AK, Simpson FC. Medical devices for the treatment of onychomycosis. Dermatol Ther 2012;25:574–81
  • Gupta AK, Humke S. The prevalence and management of onychomycosis in diabetic patients. Eur J Dermatol 2000;10:379–84
  • Gupta AK, Gupta MA, Summerbell RC, et al. The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol 2000;14:466–9
  • Abdelaziz AM, Mahmoud KM, Elsawy EM, et al. Nail changes in kidney transplant recipients. Nephrol Dial Transplant 2010;25:274–7
  • Döner N, Yasar S, Ekmekçi TR. Evaluation of obesity associated dermatoses in obese and overweight individuals. Turk Derm 2011;45:146–51
  • Gupta AK, Paquet M, Simpson FC. Therapies for the treatment of onychomycosis. Clin Dermatol 2013;31:544–54
  • Shivakumar HN, Juluri A, Desai BG, et al. Ungual and transungual drug delivery. Drug Dev Ind Pharm 2012;38:901–11
  • Jiaravuthisan M, Sasseville D, Vender R, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007:57:1–27
  • Welsh O, Vera-cabrera L, Welsh E. Onychomycosis. Clin Dermatol 2010;28:151–9
  • Pandhi D, Verma P. Nail avulsion: indications and methods (surgical nail avulsion). Indian J Dermatol Venereol Leprol 2012;78:299–308
  • Denkler K. A comprehensive review of epinephrine in the finger: to do or not to do. Plast Reconstr Surg 2001;108:114–24
  • Albom MJ. Avulsion of a nail plate. J Dermatol Surg Oncol 1977;3:34–5
  • Siegle RJ, Swanson NA. Nail surgery: a review. J Dermatol Surg Oncol 1982;8:659–66
  • Scher RK. Nail surgery. Clin Dermatol 1987;5:135–42
  • Jellinek NJ. Nail surgery: practical tips and treatment options. Dermatol Ther 2007;20:68–74
  • Baran R, Hay RJ, Garduno JI. Review of antifungal therapy and the severity index for assessing onychomycosis: part I. J Dermatolog Treat 2008;19:72–81
  • South DA, Farber EM. Urea ointment in the nonsurgical avulsion of nail dystrophies – a reappraisal. Cutis 1998;25:609–12
  • Sheehan DJ, Hitchcock CA, Carol M. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12:40–79
  • Murthy SN, Maibach HI. Topical nail products and ungual drug delivery. 1st edn. Boca Raton (FL): Taylor and Francis; 2012
  • Hui X, Lindahl A, Lamel S, Maibach H. Onychopharmacokinetics of terbinafine hydrochloride penetration from a novel topical formulation into the human nail in vitro. Drug Dev Ind Pharm 2013;39:1401–7
  • Rodgers P, Bassler M. Treating onychomycosis. Am Fam Physician 2001;63:663–73
  • Markinson BC, Monter SI, Cabrera G. Traditional approaches to treatment of onychomycosis. J Am Podiatr Med Assoc 1997;87:551–6
  • Gupta AK, Ryder JE, Baran R. The use of topical therapies to treat onychomycosis. Dermatol Clin 2003;21:481–9
  • Medicines and Healthcare Products Regulatory Agency. Public assessment report decentralised procedure: amorolfine 5% w/v nail lacquer; 2011. Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con129125.pdf [last accessed 9 Aug 2012]
  • Baran R, Tosti A, Hartmane I, et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol 2009;23:773–81
  • Subissi A, Monti D, Togni G, et al. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs 2010;70:2133–152
  • Hafeez F, Hui X, Selner M, et al. Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers. Drug Dev Ind Pharm 2014;40:838–44
  • Nair AB, Kim HD, Chakraborty B, et al. Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. J Pharm Sci 2009;98:4130–40
  • Manda P, Sammeta SM, Repka MA, et al. Iontophoresis across the proximal nail fold to target drugs to the nail matrix. J Pharm Sci 2012;1:2392–7
  • Kushwaha A, Jacob M, Shiva Kumar HN, et al. Trans-ungual delivery of itraconazole hydrochloride by iontophoresis. Drug Dev Ind Pharm 2014. [Epub ahead of print]. DOI: http://dx.doi.org/10.3109/03639045.2014.927481
  • Mididoddi P, Upadhye S, Church C, et al. Influence of etching and ultrasound on the permeability of ciclopirox through the human nail. San Antonio (TX): AAPS; 2006
  • Altshuler GB, Anderson RR, Manstein D, et al. Extended theory of selective photothermolysis. Lasers Surg Med 2001;29:416–32
  • Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983;220:524–7
  • Becker C, Bershow A. Lasers and photodynamic therapy in the treatment of onychomycosis: a review of the literature. Dermatol Online J 2013;19:19611
  • Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983;220:524–7
  • Welch AJ, Torres JH, Cheong W. Laser physics and laser tissue interactions. Tex Heart Inst J 1989;16:141–9
  • Patil UA, Dhami LD. Overview of lasers. Indian J Plast Surg 2008;41:S101–13
  • Harris F, Pierpoint L. Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent. Med Res Rev 2012;32:1292–327
  • Smijs TG, van der Haas RN, Lugtenburg J, et al. Photodynamic treatment of the dermatophyte Trichophyton rubrum and its microconidia with porphyrin photosensitizers. Photochem Photobiol 2004;80:197–202
  • Smijs TG, van der Haas RN, Lugtenburg J, et al. Photodynamic treatment of the dermatophytes Trichophyton rubrum and its microconidia with porphyrin photosensitizers. Photochem Photobiol 2004;80:197–202
  • Smijs TG, Bouwstra JA, Talebi M, et al. Investigation of conditions involved in the susceptibility of the dermatophytes Trichophyton rubrum to photodynamic treatment. J Antimicrob Chemother 2007;60:750–9
  • Smijs TG, Bouwstra JA, Schuitmaker HJ, et al. A novel ex vivo skin model to study the susceptibility of the dermatophyte Trichophyton rubrum to photodynamic treatment in different growth phases. J Antimicrob Chemother 2007;59:433–40
  • Smijs TG, Mulder AA, Pavel S, et al. Morphological changes of the dermatophytes Trichophyton rubrum after photodynamic treatment: a scanning electron microscopy study. Med Mycol 2008;46:315–25
  • Smijs TG, Pavel S, Talebi M, et al. Preclinical studies with 5,10,15-Tris(4-methylpyridinium)-20-phenyl-[21H,23H]-porphine trichloride for the photodynamic treatment of superficial mycoses caused by Trichophyton rubrum. Photochem Photobiol 2009;85:733–9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.